A recent study reported that fibroblast growth factor receptors (FGFRs) may activate RAS in a SHP2-independent manner in BRAF mutant colon and thyroid cancer cells in the setting of pathway feedback activation following treatment with BRAF inhibitors such as vemurafenib [13]. Here, BRAF is linked to thyroid gland carcinoma.